Jeil Pharma Holdings EBIT

The latest EBIT for 002620.KS is $-55B as of June 2026. That compares with $29B in the prior-year period — down 288.5% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Jeil Pharma Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, 002620.KS's EBIT moved from $29B to $-55B — a 288.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jeil Pharma Holdings's operating scale or balance-sheet position.

Against its sector companies, 002620.KS currently prints $-55B for EBIT, while the sector average sits near $2.6T. That is roughly 102.1% below the sector mean. Large gaps often invite a closer look at Jeil Pharma Holdings's growth, margins, and balance sheet.

A EBIT figure of $-55B for 002620.KS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 002620.KS's EBIT ($-55B), review year-over-year change from $29B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.